Table 1 Overview of CAR-NK studies to date using cell lines

1

Uherek (Blood 2002)

NK-92

x

HER2

x

CD3ζ

2

Schirrmann (Cancer Gene Ther 2002)

YTS

x

CEA

x

CD3ζ

3

Daldrup-Link (Eur Radiol 2005)

NK-92

x

x

HER2

x

CD3ζ

4

Schirrmann (Leukemia Research 2005)

YT

x

CD33

x

CD3ζ

5

Meier (Nucl Med Biol 2008)

NK-92

x

HER2

x

CD3ζ

6

Muller (Cancer Immunol Immunother 2008)

NK-92

x

CD20

x

murine CD3ζ

7

Tavri (Mol Imaging 2009)

NK-92

x

EpCAM

x

CD3ζ

8

Boissel (Leukemia Res 2009)

NK-92

x

x

CD19

x

CD3ζ

9

Meier (Magn Reson Med 2011)

NK-92

x

EpCAM

x

CD3ζ

10

Sahm (Cancer Immunol Immunother 2012)

NK-92, NKL

2

EpCAM

x

CD28-CD3ζ

11

Boissel (Leukemia Lymphoma 2012)

NK-92

x

x

CD19, CD20

x

CD3ζ

12

Esser (J Cell Mol Med 2012)

NK-92

x

GD2

x

CD3ζ

13

Tassev (Cancer Gene Ther 2012)

NK-92-MI

x

EBNA

x

CD3ζ

14

Alkins (Cancer Res 2013)

NK-92

x

HER2

x

CD3ζ

15

Boissel (OncoImmunol 2014)

NK-92

x

CD19, CD20

x

CD3ζ

16

Jiang (Mol Oncol 2014)

NK-92-MI

3

CD138

x

CD3ζ

17

Chu (Leukemia 2014)

NK-92

2

CS1

x

CD28-CD3ζ

18

Seidel (Cancer Immunol Immunother 2015)

NK-92

x

GD2

x

CD3ζ

19

Schönfeld (Mol Ther 2015)

NK-92

2

HER2

x

x

CD28-CD3ζ/CD137-CD3ζ/CD3ζ

20

Han (Sci Reports 2015)

NK-92, NKL

2

EGFR

x

CD28-CD3ζ

21

Clémenceau (J Immunol Res 2015)

NK-92

x

Her2

x

FceRIγ

22

Liu (Oncol Reports 2015)

NK-92

x

HER2

x

CD28-CD3ζ

23

Zhao (Leukemia 2015)

NK-92-MI

x

WT-1

x

CD137-CD3ζ

24

Muller (J Immunother 2015)

YTS

2

EGFRvIII

x

DAP12

25

Alkins (Neuro-Oncol 2016)

NK-92

x

HER2

x

CD3ζ

26

Genßler et al. (OncoImmunol 2016)

NK-92

2

EGFRvIII

x

CD28-CD3ζ

27

Zhang (J Natl Cancer Inst 2016)

NK-92

2

HER2

x

CD28-CD3ζ

28

Romanski (J Cell Mol Med 2016)

NK-92

x

CD19

x

CD3ζ

29

Topfer (J Immunother 2016)

YTS

2

EGFRvIII

x

DAP12

30

Chen (Oncotarget 2016)

NK-92, PB-NK

2

EGFR

x

CD28-CD3ζ

31

Siegler (Mol Ther 2017)

NK-92

x

x

CD19, HER2

x

x

CD28-CD137-CD3ζ/CD28-CD3ζ

32

Oelsner (Cytotherapy 2017)

NK-92

2

CD19

x

x

CD28-CD3ζ/CD137-CD3ζ/CD3ζ

33

Chen (Oncotarget 2017)

NK-92

2

CD3

x

CD137-CD28-CD3ζ

34

Chen (Leukemia 2017)

NK-92

2

CD5

x

CD137-CD28-CD3ζ

35

Li (Cell Stem Cell 2018)

NK-92, iPSC

x

mesothelin

x

x

x

2B4-CD3ζ/CD28-CD137-CD3ζ/DAP10-CD3ζ/CD137-CD3ζ/2B4-DAP12-CD3ζ/2B4-DAP10-CD3ζ/CD137-2B4-CD3ζ/CD3ζ

36

Zhao (Eur J Inflamm 2018)

NK-92-MI

x

CD19, CD138

x

CD28-CD3ζ

37

Murakami (Anticancer Res 2018)

KHYG-1

x

EGFRvIII

x

CD137-CD3ζ

38

Zhang (J Immunol Res 2018)

NK-92

2

EpCAM

x

CD137-CD3ζ

39

Yu (Mol Therapy 2018)

NK-92

x

GPC3

x

CD28-CD3ζ

40

Nowakowska (Cancer Immunol Immunother 2018)

NK-92

2

HER2

x

x

CD28-CD3ζ/CD137-CD3ζ/CD3ζ

41

Tang (Am J Cancer Res 2018)

NK-92-MI

3

CD33

x

x

CD28-CD137-CD3ζ

42

Schnalzger (EMBO J 2019)

NK-92

2

HER2

x

CD28-CD3ζ

43

Ao (J Immunother 2019)

NK-92

x

AlphaFR

x

x

x

CD3ζ/CD28-CD3ζ/CD28-CD137-CD3ζ

44

Kloess (Human Gene Therapy 2019)

NK-92, PB

x

CD123

x

CD28-CD137-CD3ζ

45

Kim (Biomaterials 2019)

NK-92-MI

x

EGFR

x

CD28-CD3ζ

46

Xu (J Hematol Oncol 2019)

NK-92

3

CD5

x

2B4-CD3ζ/CD137-CD3ζ

47

Batchu (Surgery 2019)

NK-92-MI

x

x

mesothelin

x

CD28-CD137-CD3ζ

48

Kulemzin (BMC Med Genom 2019)

NK-92, YT

2

PMSA

x

CD28-CD3ζ

49

You (Am J Cancer Res. 2019)

NK-92-MI

x

CD7

x

CD28-4-1BB-CD3ζ

50

Oelsner (Int J Cancer 2019)

NK-92

2

FLT3

x

CD28-CD3ζ

51

Parlar (Eur J Immunol 2019)

NK-92, YTS

x

CD3 δγεδ, TCR

x

CD3ζ

52

Mensali (EBioMed 2019)

NK-92

x

CD3 δγεδ, TCR

x

CD3ζ

53

Ravi (Leukemia 2020)

NK-92

x

CD19

x

CD3ζ

54

Hu (Sci Report 2020)

NK-92-MI

x

Tissue factor

x

CD137-CD3ζ

55

Huang (Cancer Manag Res 2020)

NK-92

x

GPC3

x

x

x

CD3ζ/CD28-CD3ζ/2B4-CD3ζ/DNAM1-CD3ζ/DNAM1-2B4-CD3ζ

56

Mitwasi (Sci Report 2020)

NK-92-MI

x

GD2

x

CD28-CD3ζ

57

Hambach (Cells 2020)

NK-92

x

CD38

x

CD28-CD137-CD3ζ

58

Cao (Biochem Biophys Res Commun 2020)

NK-92

2

Mesothelin, CD19

x

CD28-CD137-CD3ζ

59

Li (J Cancer Res Ther 2020)

NK-92

x

Robo1

x

CD137-CD3ζ

60

Montagner (Cells 2020)

NK-92

x

PMSA

x

CD28-CD3ζ

61

Nakazawa (Anticancer Res 2020)

KHYG-1

x

EGFRvIII

x

CD137-CD3ζ

62

Robbins (eLife 2020)

NK-92

–

–

–

–

–

PDL1

x

FcεR1γ

63

Lee (J Control Release 2020)

NK-92

x

Fra, TRAIL

x

CD27-CD3ζ

64

Liu (Cytotherapy 2020)

NK-92 MI

3

CD19

x

CD137-CD3ζ

65

Yang (Front Pharmacol 2020)

NK-92 MI

2

B7H3

x

CD137-CD3ζ

66

Jamali (Front immunol 2020)

NK-92, NKL, PB

3

CD19

x

CD137-CD3ζ

67

Ahn (Biomaterials 2020)

NK-92

–

–

–

–

–

EGFR

x

CD28-DAP10-CD3ζ

68

Fabian (J Immunother Cancer 2020)

haNK-92

–

–

–

–

–

PD-L1

–

–

–

–

69

Gurney (Haematologica 2020)

KHYG-1, PB-NK

x

CD38

x

CD28-CD3ζ

70

Tseng (Nat Commun 2020)

NK-92MI, PB-NK

x

2

CD147, GPC3

x

CD28-CD137-CD3ζ

71

Eitler (Journal for ImmunoTherapy of Cancer 2021)

NK-92

2

HER2

x

CD28-CD3ζ

72

Kang (Int J Mol Sci 2021)

NK-92MI, KHYG-1

3

CD19

CD28-CD3ζ